An Interactive Case Review

Through expert analysis of current treatment paradigms, this CME program will provide a comprehensive review of emerging clinical advances and challenges regarding the development of novel targeted agents for the treatment of breast cancer and whether or not these agents can be combined rationally to improve patient outcomes while avoiding unwarranted toxicities.

Expert Discussion Panel

Advances in Targeted Therapies for Breast Cancer Kathy D. Miller, MD Sheila D. Ward Scholar Department of Medicine Division of Hematology/Oncology Associate Professor of Medicine Indiana University School of Medicine Indiana University Melvin and Bren Simon Cancer Center Indianapolis, IN Topics include: HER2 Positive Disease Trastuzumab Lapatinib HER2 testing New agents in development Angiogenesis Bevacizumab and bevacizumab-containing regimens Small molecule success and disappointment Review of Key Clinical Trials E2100 RIBBON-1 AVADO RIBBON-2 SOLTI-0701

Available until May 2011, this activity offers:
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hour
Pharmacists: 1.0 contact hour (0.10 CEU)

This activity is made possible by an educational grant from Genentech.
 

 

[Back to top]

[Back to Activity Home]